Proprietary AI analyst is now available

Johnson & Johnson Valuation Multiples

Discover Johnson & Johnson's revenue and EBITDA valuation multiples, acquisitions, and investment history, alongside public comparables like AbbVie, Roche, Merck, Novartis and more.

Johnson & Johnson Overview

About Johnson & Johnson

Johnson & Johnson is the world's largest and most diverse healthcare firm. It has two divisions: innovative medicine and medtech. These now represent all of the company's sales following the divestment of the consumer business, Kenvue, in 2023. After restructurings in 2023-24, the drug division focuses on three main therapeutic areas: immunology, oncology, and neurology. Geographically, just over half of total revenue is generated in the United States.


Founded

1887

HQ

United States

Employees

138.2K

Website

jnj.com

Financials (LTM)

Revenue: $97B
EBITDA: $36B

EV

$593B

Valuation Multiples

Start free trial

Valuation Multiples for 15K+ Public Comps

AdidasAirbnbAmazonCiscoCoca-ColaDellDropboxIBMIntelMcDonaldsNikeNVIDIASamsungSpotifyTeslaToyota
Browse Valuation Multiples

Johnson & Johnson Financials

Johnson & Johnson reported last 12-month revenue of $97B and EBITDA of $36B.

In the same LTM period, Johnson & Johnson generated $70B in gross profit, $36B in EBITDA, and $27B in net income.

Revenue (LTM)


Johnson & Johnson P&L

In the most recent fiscal year, Johnson & Johnson reported revenue of $94B and EBITDA of $41B.

Johnson & Johnson is profitable as of last fiscal year, with gross margin of 68%, EBITDA margin of 44%, and net margin of 28%.

See analyst estimates for Johnson & Johnson
LTMLast FY202320242025202620272028
Revenue$97B$94B$95B$89B$94B
Gross Profit$70B$64B$64B$61B$64B
Gross Margin72%68%67%69%68%
EBITDA$36B$41B$29B$25B$41B
EBITDA Margin37%44%31%28%44%
EBIT Margin33%32%26%24%27%
Net Profit$27B$27B$18B$14B$27B
Net Margin28%28%19%16%28%
Net Debt-$28B---

Financial data powered by Morningstar, Inc.

Johnson & Johnson Stock Performance

Johnson & Johnson has current market cap of $560B, and enterprise value of $593B.

Market Cap Evolution


Johnson & Johnson's stock price is $232.77.

Johnson & Johnson share price increased by 3.3% in the last 30 days, and by 52.4% in the last year.

Johnson & Johnson has an EPS (earnings per share) of $11.13.

See more trading valuation data for Johnson & Johnson
EVMarket CapPrice 1DPrice 1MPrice 3MPrice 12MEPS
$593B$560B2.0%3.3%-4.8%52.4%$11.13

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.

Start Free Trial

Johnson & Johnson Valuation Multiples

Johnson & Johnson trades at 6.1x EV/Revenue multiple, and 16.3x EV/EBITDA.

See NTM and 2027E valuation multiples for Johnson & Johnson

EV / Revenue (LTM)


Johnson & Johnson Financial Valuation Multiples

As of June 6, 2026, Johnson & Johnson has market cap of $560B and EV of $593B.

Johnson & Johnson has a P/E ratio of 20.7x.

LTMLast FY202320242025202620272028
EV/Revenue6.1x6.3x6.2x6.7x6.3x
EV/EBITDA16.3x14.5x20.5x23.9x14.5x
EV/EBIT18.7x19.5x24.2x27.9x23.2x
EV/Gross Profit8.5x9.3x9.3x9.7x9.3x
P/E20.7x20.9x31.2x39.8x20.9x
EV/FCF25.4x27.8x34.5x32.9x30.7x

Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Verified Johnson & Johnson Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.

FactSetMorningstar
Start Free Trial

Johnson & Johnson Margins & Growth Rates

Johnson & Johnson grew revenue by 7% but EBITDA decreased by 7% in the last fiscal year.

In the most recent fiscal year, Johnson & Johnson reported gross margin of 68%, EBITDA margin of 44%, and net margin of 28%.

See estimated margins and future growth rates for Johnson & Johnson

Johnson & Johnson Margins

Last FY202420252026202720282029
Gross Margin68%69%68%72%
EBITDA Margin44%28%44%38%
EBIT Margin32%24%27%33%
Net Margin28%16%28%28%
FCF Margin23%20%21%26%

Johnson & Johnson Growth Rates

FY+1/FY23/2424/2525/2626/2727/2828/29
Revenue Growth7%(6%)6%7%
Gross Profit Growth13%(4%)4%13%
EBITDA Growth(7%)(14%)66%(7%)
EBIT Growth10%(13%)20%31%
Net Profit Growth5%(22%)91%5%
FCF Growth22%5%7%35%

Data powered by FactSet, Inc. and Morningstar, Inc.

Johnson & Johnson Operational KPIs

Johnson & Johnson's revenue per employee in the last FY averaged $0.7M, while opex per employee averaged $0.3M for the same period.

Johnson & Johnson's Rule of 40 is 45% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

Johnson & Johnson's Rule of X is 56% (created by Bessemer, Rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

Access forward-looking KPIs for Johnson & Johnson
LTMLast FY202320242025202620272028
Rule of 4044%45%---
Bessemer Rule of X55%56%---
Revenue per Employee-$0.7M---
Opex per Employee-$0.3M---
R&D Expenses to Revenue15%16%15%19%16%
Opex to Revenue-41%41%45%41%

Data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 230+ Verticals

Johnson & Johnson Competitors

Johnson & Johnson competitors include AbbVie, Roche, Merck, Novartis, AstraZeneca, Siemens, Novo Nordisk, Amgen, Eli Lilly and Samsung.

Most Johnson & Johnson public comparables operate across Biopharmaceuticals, Medical Devices, BioTech, DeepTech and HealthTech.

EV/RevenueEV/EBITDA
Last FYLTM2027ELast FYLTM2027E
AbbVie7.6x7.3x19.2x16.8x
Roche-4.4x-11.2x
Merck5.3x5.2x11.5x13.0x
Novartis5.7x5.9x14.1x14.2x
AstraZeneca5.3x-15.8x-
Siemens3.0x2.9x15.1x16.5x
Novo Nordisk4.4x4.6x8.8x9.4x
Amgen6.4x6.3x13.8x13.7x

This data is available for Pro users. Sign up to see all Johnson & Johnson competitors and their valuation data.

Start Free Trial

Acquisitions by Johnson & Johnson

Johnson & Johnson has acquired 27 companies to date.

Last acquisition by Johnson & Johnson was on April 23rd 2026. Johnson & Johnson acquired Atraverse Medical for undisclosed valuation.

See M&A valuation multiples

Latest Acquisitions by Johnson & Johnson

Atraverse Medical
Halda Therapeutics
OBaris
Intra-Cellular Therapies
Description
-
Halda Therapeutics is a clinical-stage biopharmaceutical company developing precision oncology therapies using its proprietary macrocyclic peptide platform. Founded in 2020 and based in London, United Kingdom, the firm targets undruggable protein-protein interactions in cancer pathways. Its lead candidate, HTX-101, entered Phase I trials in 2023 for solid tumors, backed by $30 million in Series A funding from investors including Oxford Science Enterprises.
OBaris is a Lausanne, Switzerland-headquartered biotechnology firm developing the OctoPatch needle-free drug delivery platform. The microneedle patch administers biologics like insulin and vaccines through the skin in Basel and Zurich clinics. OBaris conducts clinical trials in Europe for chronic disease management applications.
Intra-Cellular Therapies is a New York-based biopharmaceutical firm developing CNS disorder treatments. Listed on NASDAQ as ITCI, the company markets Caplyta (lumateperone), approved in 2019 for schizophrenia and 2021 for bipolar depression in adults. Intra-Cellular Therapies advances ITI-007 for adjunctive therapy and explores candidates for Alzheimer's psychosis and postpartum depression. Its CNSProfile platform analyzes intracellular drug signaling for novel compound discovery.
HQ CountryUnited StatesUnited StatesSwitzerlandUnited States
HQ City
Chicago, IL
New Haven, CT
Zurich
New York City, NY
Deal Date23 Apr 202617 Nov 20253 Sep 202513 Jan 2025
Valuationundisclosed$3Bundisclosed$15B
EV/Revenue
EV/EBITDA

This data is available for Pro users. Sign up to see all Johnson & Johnson acquisitions and their M&A valuation multiples.

Start Free Trial

Investments by Johnson & Johnson

Johnson & Johnson has invested in 6 companies to date.

Latest investment by Johnson & Johnson was on December 12th 2024. Johnson & Johnson invested in Alessa Therapeutics in their $15M Seed round (EV/Revenue multiple available to Pro users).

See VC round multiples

Latest Investments by Johnson & Johnson

Alessa Therapeutics
Ready, Set, Food!
SwipeRx
Ready, Set, Food!
Description
Alessa Therapeutics is a Basel-based preclinical biopharma developing nanoparticle-based therapies for localized treatment of solid tumors in liver and pancreas. Its lead candidate, AT-108, delivers chemotherapy directly to cancer sites minimizing systemic toxicity. The company partners with academic centers in Switzerland for clinical translation. Incorporated in 2020, Alessa has secured seed funding from European VCs focused on oncology innovations.
Ready, Set, Food! is a San Francisco-based company offering early allergen introduction systems to reduce food allergy risks in infants by up to 80 percent through daily dissolvable strips and pouches. Products target peanut, egg, and milk allergens, starting at four months under pediatric guidance. Backed by clinical trials published in the New England Journal of Medicine, it serves over 100,000 families. Founded in 2018, the kits comply with FDA guidelines and integrate with apps for progress tracking.
Manila-based SwipeRx delivers a digital platform connecting independent pharmacies across the Philippines. The service offers compliant healthcare logistics, negotiated supplier pricing, and financing options to over 30,000 pharmacies. As Southeast Asia's largest pharmacy purchasing network, it facilitates bulk procurement of medicines and health products, reducing costs and improving supply chain efficiency for community pharmacies.
Ready, Set, Food! is a San Francisco-based company offering early allergen introduction systems to reduce food allergy risks in infants by up to 80 percent through daily dissolvable strips and pouches. Products target peanut, egg, and milk allergens, starting at four months under pediatric guidance. Backed by clinical trials published in the New England Journal of Medicine, it serves over 100,000 families. Founded in 2018, the kits comply with FDA guidelines and integrate with apps for progress tracking.
HQ CountryUnited StatesUnited StatesSingaporeUnited States
HQ City
San Francisco, CA
Los Angeles, CA
Singapore
Los Angeles, CA
Deal Date12 Dec 20241 Jan 20249 Feb 20231 Jan 2022
RoundSeedSeries ASeries BSeries A
Raised$15M$7M$10M$20M
InvestorsJohnson & Johnson; Mission BioCapitalDanone Manifesto Venture; Johnson & Johnson; Providence Health & ServicesCercano Management; Johnson & Johnson; Patamar Capital; Sanofi; Susquehanna International GroupAllerFund; Danone Manifesto Venture; Johnson & Johnson; Memorial Hermann Health System; Providence Health & Services; Tech Coast Angels; Wavemaker 360
Valuationundisclosedundisclosedundisclosedundisclosed
EV/Revenue
EV/EBITDA

This data is available for Pro users. Sign up to see all Johnson & Johnson investments and their VC round multiples.

Start Free Trial

Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples

Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.

Start Free Trial

About Johnson & Johnson

When was Johnson & Johnson founded?Johnson & Johnson was founded in 1887.
Where is Johnson & Johnson headquartered?Johnson & Johnson is headquartered in United States.
How many employees does Johnson & Johnson have?As of today, Johnson & Johnson has over 138K employees.
Who is the CEO of Johnson & Johnson?Johnson & Johnson's CEO is Joaquin Duato.
Is Johnson & Johnson publicly listed?Yes, Johnson & Johnson is a public company listed on NYSE.
What is the stock symbol of Johnson & Johnson?Johnson & Johnson trades under JNJ ticker.
When did Johnson & Johnson go public?Johnson & Johnson went public in 1944.
Who are competitors of Johnson & Johnson?Johnson & Johnson main competitors include AbbVie, Roche, Merck, Novartis, AstraZeneca, Siemens, Novo Nordisk, Amgen, Eli Lilly, Samsung.
What is the current market cap of Johnson & Johnson?Johnson & Johnson's current market cap is $560B.
What is the current revenue of Johnson & Johnson?Johnson & Johnson's last 12 months revenue is $97B.
What is the current revenue growth of Johnson & Johnson?Johnson & Johnson revenue growth (NTM/LTM) is 7%.
What is the current EV/Revenue multiple of Johnson & Johnson?Current revenue multiple of Johnson & Johnson is 6.1x.
What is the current EBITDA of Johnson & Johnson?Johnson & Johnson's last 12 months EBITDA is $36B.
What is Johnson & Johnson's EBITDA margin?Johnson & Johnson's last 12 months EBITDA margin is 37%.
What is the current EV/EBITDA multiple of Johnson & Johnson?Current EBITDA multiple of Johnson & Johnson is 16.3x.
What is the current FCF of Johnson & Johnson?Johnson & Johnson's last 12 months FCF is $23B.
What is Johnson & Johnson's FCF margin?Johnson & Johnson's last 12 months FCF margin is 24%.
What is the current EV/FCF multiple of Johnson & Johnson?Current FCF multiple of Johnson & Johnson is 25.4x.
How many companies Johnson & Johnson has acquired to date?As of June 2026, Johnson & Johnson has acquired 27 companies.
What was the largest acquisition by Johnson & Johnson?$30B acquisition of Actelion Pharmaceuticals on 26th January 2017 was the largest M&A Johnson & Johnson has done to date.
In how many companies Johnson & Johnson has invested to date?As of June 2026, Johnson & Johnson has invested in 6 companies.
What was the last Johnson & Johnson investment?On 12th December 2024 Johnson & Johnson invested in Alessa Therapeutics, participating in a $15M Seed round, alongside Mission BioCapital.
In what companies Johnson & Johnson invested in?Johnson & Johnson invested in Cue Health, Dreem, DayTwo, Ready, Set, Food!, Alessa Therapeutics, and SwipeRx.

See public comps similar to Johnson & Johnson

Lists including Johnson & Johnson

Start Your
Free Trial Today

Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.

Start Trial